Kalen Jackson is carrying on her father's legacy through her mental health advocacy
It's
personal for Kalen Jackson
, too.
Irsay's youngest daughter, who joins sisters Carlie Irsay-Gordon and Casey Foyt in
running the team
, has talked openly about dealing with anxiety. Irsay-Gordon is the CEO with Foyt as executive vice president and Jackson chief brand officer.
Jackson leads 'Kicking The Stigma,' the family's initiative to raise awareness about mental health disorders. The organization is committed to dismantling the stigma often associated with these illnesses and has been focused on expanding access to critical services across Indiana and nationwide.
The Colts have donated more than $30 million to nonprofits and organizations in the mental health space since the initiative launched in 2020.
'The stigma piece to me has almost become synonymous in my head with the way we handle it as a culture because the stigma comes from prejudice and judgment and that comes from how it's presented in our culture over time,' Jackson said. 'How do we change that conversation? With that will come so much of the change that we're fighting so hard to get to in terms of having more things covered (by) insurance or the way the hospital networks look at this, the way that companies look at this and supporting their employees.'
Irsay often spoke publicly about his
battles with alcoholism and addiction
, hoping his journey to sobriety would inspire and encourage others.
Jackson's voice will continue to carry on the conversation.
'I am so proud of the legacy he has left behind and I only hope to make him proud,' Jackson said.
Jackson will be recognized by
Project Healthy Minds
, a Millennial and Gen Z-driven mental health tech nonprofit, for becoming a trailblazing leader in mental health advocacy. She will receive the organization's first 'Sports Visionary of the Year' Award at the third annual World Mental Health Day Gala on Oct. 9 in New York. NFL Commissioner Roger Goodell will present Jackson with the award at an event that's brought together celebrities, executives, and cultural leaders, including Prince Harry and Meghan Markle.
'When we all got together to decide who should win this inaugural award, it was unanimous that it should be Kalen and the Colts because they have been so committed to mental health in sports,' said Phillip Schermer, founder and CEO of Project Healthy Minds. 'It's not talking the talk, it's walking the walk. They've been doing this from the beginning and I think they've sort of lit a path for what I think every sport and every league ought to do.'
For Jackson, who is on the nonprofit's Board of Directors, the mission is clear.
'To connect with people and to be compassionate and to try to change the world for the better, that's kind of what all this is for me,' she said.
The NFL and NFL Players Association in 2019 agreed to make it a requirement to have a licensed behavioral health clinician on the staff of each team in an effort to increase mental health resources.
The Colts have taken it further. They recently hired a clinician to also work with front-office staff and coaches.
'I don't have to wait to know what impact it's going to have,' Jackson said.
___
AP NFL:
https://apnews.com/hub/nfl
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
NFL Biosciences Announces a Scientific Collaboration with McLean Hospital (Boston, USA) to Further Investigate the Mechanism of Action of NFL-101
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 - ALFNL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, today announces the launch of a scientific collaboration with McLean Hospital, a member of the Mass General Brigham healthcare system in Boston, USA. This new collaboration aims to deepen the understanding of the mechanism of action of NFL-101, its proprietary botanical drug candidate for smoking cessation. This collaboration follows studies conducted with the Georges Pompidou European Hospital (HEGP) and the French Alternative Energies and Atomic Energy Commission (CEA) which highlighted NFL-101's ability to restore normal brain activity in regions associated with tobacco craving, particularly the thalamus, during withdrawal. This restoration proved to be both specific and sustained. These results suggest the existence of a unique mechanism of action involving an interaction between the immune system and the central nervous system, distinct from existing treatments that directly target nicotinic receptors. The studies conducted by McLean Hospital will explore in greater detail the links between this brain activity restoration and established biomarkers of tobacco addiction, with the objective of further characterizing NFL-101's pharmacological profile. Three laboratories at McLean Hospital, will be involved in this project: the Integrative Neurochemistry Laboratory, the Behavioral Neuroimaging Laboratory, and the Behavioral Psychopharmacology Research Laboratory. This collaboration represents a strategic milestone aligned with the upcoming Phase III trial. It also supports NFL Biosciences' international expansion, particularly in the United States, through collaborations with world-renowned experts in addiction science. The results will further strengthen NFL Biosciences' regulatory submission. Launched at a pivotal time, this initiative contributes to the momentum of ongoing discussions with potential industrial partners. Under this agreement, NFL Biosciences will retain exclusive intellectual property rights, including any potential patent applications resulting from the work conducted jointly with McLean Hospital. The results of this collaboration may lead to co-authored publications in peer-reviewed scientific journals and presentations at international conferences by the McLean Hospital research teams involved in the project. These studies will further enhance the scientific visibility of the NFL-101 program. Professor Scott Lukas, Director of the McLean Imaging Center and the Behavioral Psychopharmacology Research Laboratory at McLean Hospital (USA), stated: 'With botanical drugs, efficacy often relies on the full extract, making it challenging to identify a precise mechanism of action. Too often, we develop molecules with a clearly defined mechanism, yet based on an incomplete understanding of addiction pathways, which frequently leads to setbacks in clinical trials. Here, it's the opposite: we already have demonstrated clinical effects, and the mechanism remains to be further explored. The next stage is to better understand the mechanism of action, which could strengthen the scientific rationale for the treatment and open the door to additional therapeutic insights, including potential individualized approaches.' Bruno Lafont, Chief Executive Officer and co-founder of NFL Biosciences commented: 'We are delighted to collaborate with McLean Hospital on this research project. Following the teams at the CEA and the Georges Pompidou European Hospital, this new collaboration further strengthens our program with complementary world-class expertise, particularly in addiction science and botanical drug pharmacology. It represents a key milestone in our commitment to deepen the understanding of NFL-101's mechanism of action and enhance its scientific and industrial appeal.' About McLean Hospital McLean Hospital has a continuous commitment to put people first in patient care, innovation and discovery, and shared knowledge related to mental health. It is consistently named the #1 freestanding psychiatric hospital in the United States by U.S. News & World Report and is #2 in America for psychiatric care in 2024-25. McLean Hospital is the largest psychiatric affiliate of Harvard Medical School and a member of Mass General Brigham. To stay up to date on McLean, follow us on Facebook, YouTube, and LinkedIn. About NFL Biosciences: NFL Biosciences is a biopharmaceutical company based in the Montpellier region of France, developing plant-based drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, safer and more effective natural therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, NFL-101, is a standardized tobacco leaf extract protected by three patent families. NFL Biosciences intends to offer smokers wishing to quit a natural, safe, easy-to-administer and personalized alternative. NFL Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorders. NFL Biosciences shares are listed on Euronext Growth Paris (FR0014003XT0 - ALNFL). The company is qualified as an 'Innovative Company' eligible for FCPI investment. More information on
Washington Post
2 days ago
- Washington Post
Broncos linebacker Drew Sanders carted off practice field with right leg injury
ENGLEWOOD, Colo. — Third-year linebacker Drew Sanders was carted off the Denver Broncos' football fields Saturday after injuring his right leg during drills. Sanders began hopping around right after the play and then went to the ground in pain. Team medical personnel looked at his right foot and ankle before putting him on a cart and taking him inside team headquarters for an MRI.
Forbes
3 days ago
- Forbes
Raiders' Release Of Christian Wilkins May Conflict With Medical Autonomy Provided For In CBA
Photo byOn July 24, the Las Vegas Raiders reportedly released defensive tackle Christian Wilkins, a six-year veteran with whom the Raiders signed a four-year, $110 million contract prior the 2024 season, $82.75 million of which was guaranteed. The Raiders were reportedly unhappy with the progress on Wilkins' recovery from a foot injury suffered last season, including a disagreement with Wilkins about whether additional surgery was needed. The Raiders' position – and the related voiding of Wilkins' contract – potentially runs afoul of player protections in the collective bargaining agreement (CBA) between the NFL and NFLPA, resulting in a grievance filed by the NFLPA. Bioethical Considerations The situation raises serious bioethical concerns. Bioethics refers to the application of ethics – the philosophical discipline pertaining to notions of right and wrong – to the fields of medicine and healthcare. Bioethical analyses are generally conducted through the lens of specific principles, the most commonly-recognized being respect for autonomy, non-maleficence (the duty to avoid harm), beneficence (the duty to do good), and justice. Of most relevance to Wilkins' situation is the concept of autonomy. As described by leading bioethicists Tom Beauchamp and James Childress, '[p]The Raiders' apparent insistence that Wilkins have another surgery despite his preference otherwise appears to run afoul of the principle of autonomy, i.e., the right to control what is done to one's own body. The Raiders' actions could be viewed as self-serving, or at a minimum paternalistic (a question that has arisen with Miami Dolphins quarterback Tua Tagovailoa). Who Decides? The Raiders' position also raises legal issues, as evidenced by the NFLPA's grievance. Specifically, Section 6 of Article 39 of the CBA protects a player's right to receive a second medical opinion from a doctor of his choice and at the team's expense after having been first examined by the team's doctor. That provision also provides that a 'player shall have the right to follow the reasonable medical advice given to him by his second opinion physician with respect to diagnosis of injury, surgical and treatment decisions, and rehabilitation and treatment protocol, but only after consulting with the Club physician and giving due consideration to his recommendations.' This provision is generally understood to provide players with the ultimate right to choose their own course of treatment, consistent with the principle of autonomy. Additionally, if surgery is required, players are permitted to utilize an appropriately qualified surgeon of their choosing. The right of NFL players to control their medical treatment is not an approach shared by all sports leagues. While MLB also permits players to make the final decision about their treatment, the NBA, NHL and MLS CBAs provide the clubs with the right to determine a player's course of treatment. (See here for a report I co-authored in 2017 comparing the health-related policies and practices of the different leagues.) Indeed, this right was a major issue for NHL players in their recent CBA negotiations with the league after a dispute between Jack Eichel and the Buffalo Sabres concerning treatment for a neck and back injury. Whether such a right is now provided for in the recently agreed to CBA has not been publicly revealed and the NHLPA did not immediately respond to a request for comment. The Value Of A Guarantee The NFLPA is also likely taking the position that the Raiders' release of Wilkins violated his contract, including specifically the $35.2 million remaining in guaranteed compensation. Portions of NFL player contracts can be 'guaranteed' in a variety of ways. Under the standard NFL player contract, a player's contract can be terminated if: (1) 'at any time, in the sole judgment of Club, Player's skill or performance has been unsatisfactory as compared with that of other players competing for positions on Club's roster…, [or (2)] during the period any salary cap is legally in effect…, in Club's opinion, Player is anticipated to make less of a contribution to Club's ability to compete on the playing field than another player or players whom Club intends to sign or attempts to sign, or another player or players who is or are already on Club's roster, and for whom Club needs room.' Player contracts frequently provide that they will continue to receive some portion of their pay despite these two termination rights, known as 'skill' and 'cap' guarantees. Additionally, player contracts also frequently guarantee that a player will continue to receive his pay despite having suffered an injury. While the player's contract and CBA generally require a player to be paid their salary for so long as they are physically unable to provide their services because of an on-field injury, the duration of the injury and the required payment are frequently a subject of dispute and resolved through a process known as an Injury Grievance. An injury guarantee avoids this uncertainty and offers the player broader protection against release as a result of an injury. ESPN's report indicates that the Raiders' reason for the release was because Wilkins had failed 'to maintain his physical condition to play.' Wilkins and the NFLPA undoubtedly believe that the real reason for his release stems from Wilkins' on-field injury and that failing to continue paying him will violate injury guarantees in his contract. The dispute will now be resolved before a neutral arbitrator. In the meantime, Wilkins is free to sign with another club. And in the event Wilkins prevails in his grievance, the Raiders will likely claim that any pay Wilkins received from another club should offset any amounts owed by the Raiders. The Raiders did not respond to request for comment and the NFLPA declined to comment about Wilkins' situation.
